Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma

Haemostasis

Volumn 30, Issue 3, 2000, Pages 123-130

  Mischke, R ^a,b   Wolling, H ^a  

^a School of Veterinary Medicine   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Coagulation tests; Dog; Fibrinogen degradation products

Indexed keywords

FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT;

ARTICLE; BINDING SITE; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; DOG; FIBRIN POLYMERIZATION; FIBRINOLYSIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME;

EID: 0033803758     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022534     Document Type: Article

References (21)

1. Feldman BF: Diagnostic approaches to coagulation and fibrinolytic disorders. Semin Vet Med Surg (Small Anim) 1992;7:315-322.
2. Barth A, Furlan M. Lämmle B: Unerwartet verlängerte Thrombinzeit. Schweiz Med Wochenschr 1993; 123:523-529.
3. Latallo ZS, Budzynski AZ, Lipinski B, Kowalski E: Inhibition of thrombin and of fibrin polymerization, two activities derived from plasmin-digested fibrinogen. Nature 1964; 203:1184-1185.
4. Marder VJ, Shulman NR: High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J Biol Chem 1969;244: 2110-2124.
5. Larrieu MJ, Rigollot C, Marder VJ: Comparative effects of fibrinogen degradation fragments D and E on coagulation. Br J Haematol 1972; 22:719-733.
6. Wenzel E, Holzhüter H, Muschictti F Angelkort B, Ochs HG, Pusztai-Markes S, Nowak H, Stürmer H: Zuverlässigkeit des Fibrinogen-(Fi-brin)-Spaltproduktnachweises im Plasma mit Thrombinkoagulase-, Reptilase- und Thrombingerinnungszeit. Dtsch Med Wochenschr 1974;99:746-756.
7. Chen JP, Hutchison HAT, Nanninga LB, Mason Guest M: Characterization of the terminal degradation products of canine fibrinogen by plasmin. Biochim Biophys Acta 1975;386:69-79.
8. Haverkate F, Timan G, Nieuwenhuizen W: Anticlotting properties of fragments D from human fibrinogen and fibrin. Eur J Clin Invest 1979;9: 253-255.
9. Nieuwenhuizen W, Gravesen M: Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen, produced by plasmin (fragments X). Biochim Biophys Acta 1981;668: 81-88.
10. Nieuwenhuizen W, Voskuilen M, Hermans J: Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen (plasmin fragments Y). Biochim Biophys Acta 1982:708: 313-316.
11. Wolling H, Mischke R: Präparation und Reinigung von Milligramm-Mengen der caninen Fibrinogenspaltprodukte (FSP) -X, -Y, -D und -E. Berl Münch Tierärztl Wochenschr 1995;108:421-426.
12. Kazal LA, Amsel S, Miller OP, Tocantins LM: The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963;113:989-994.
13. Heukoshoven J, Dernick R: Improved silver staining procedure for fast staining in Phast System development unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis 1988:9:28-32.
14. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-254.
15. Jacobsson K: Studies on fibrinogen. I. Studies on the determination of fibrinogen in human blood plasma. Scand J Clin Lab Invest 1955;7:1-54.
16. Gaffney PJ: Fibrin(-ogen) interactions with plasmin. Haemostasis 1977;6:2-25.
17. Marder VJ, Shulman NR: High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969;244:2111-2119.
18. Wolling H, Mischke R: Einfluss von Calcium-Ionen auf die Spaltung von caninem und humanem Fibrin(ogen) durch (human-)Plasmin. Berl Münch Tierärztl Wochenschr 1995; 108;373-379.
19. Cooper HA, Bowie EJW, Owen CA: Evaluation of patients with increased fibrinolytic split products (FSP) in their serum. Mayo Clin Proc 1974;49:654-657.
20. Sato N, Takahashi H, Shibata A: Fibrinogen/fibrin degradation products and D-dimer in clinical practice: Interpretation of discrepant results. Am J Hematol 1995;48:168-174.
21. Hammer AS, Couto CG, Swardson C, Getzy D: Hemostatic abnormalities in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:11-14.